Caris Life Sciences, Inc. (CAI)
↓ Download CSV- Sector Services
- Incorporated TX
- Fiscal year ends Dec 31
In fiscal 2025, Caris Life Sciences, Inc. reported revenue of $812.03M, up 97.0% from the prior year. The company ran a net loss, with a net margin of -8.4%. It held $1.13B in total assets against $548.36M in total liabilities.
Key ratios (FY2025)
5.6%
Operating margin
-8.4%
Net margin
-11.8%
Return on equity
+97.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $812.03M | $412.26M | $306.13M | — |
| Operating Income | $45.11M | -$257.12M | -$319.55M | — |
| Net Income | -$68.09M | -$281.89M | -$341.42M | — |
| EPS (Diluted) | $-3.22 | $-10.66 | $-13.24 | — |
| Total Assets | $1.13B | $343.73M | — | — |
| Total Liabilities | $548.36M | $620.92M | — | — |
| Shareholders' Equity | $577.31M | -$2.50B | -$2.14B | -$1.70B |
| Cash & Equivalents | $796.27M | $63.95M | — | — |
| Operating Cash Flow | $83.16M | -$245.20M | -$276.10M | — |
| Capital Expenditures | $16.26M | $8.44M | $22.32M | — |
| Shares Outstanding | 167.21M | 35.50M | 34.94M | — |